Veradigm to Participate in Barclays 26th Annual Global Healthcare Conference

3/4/24 7:00:00 AM ET

EDP Services

Technology

Get the next $MDRX alert in real time by email

Veradigm Inc. (OTC:MDRX), a leading provider of healthcare data and technology solutions announced today that Dr. Yin Ho, Veradigm interim Chief Executive Officer and board member, Lee Westerfield, interim Chief Financial Officer, and Will Manidis, Senior Vice President and the former CEO of ScienceIO, will participate in a fireside chat and investor Q&A, as well as meet with investor attendees during the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, 2024 at 2:05 PM EDT.

The webcast will be available in the investor section of the company's website at investor.veradigm.com, with an archived version accessible later that same day.

About Veradigm®

Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240304311735/en/

Get the next $MDRX alert in real time by email

Recent Analyst Ratings for

$MDRX

Date	Price Target	Rating	Analyst
3/19/2024	$15.00 → $10.00	Buy → Hold	Deutsche Bank
1/3/2024	$11.00	Equal Weight	Barclays
7/6/2023		Buy → Hold	Argus
4/12/2023	$13.00	Equal-Weight	Stephens
2/1/2023	$17.00 → $18.50	Overweight → Neutral	Piper Sandler
12/7/2022	$26.00	Hold → Buy	Argus
11/9/2022	$22.00 → $23.00	Neutral → Buy	Goldman
11/4/2022	$17.00	Overweight	Piper Sandler

More analyst ratings

Veradigm to Participate in Barclays 26th Annual Global Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $MDRX

$MDRX Leadership Updates

Live Leadership Updates

Sprinklr Set to Join S&P SmallCap 600

Omnicell Elects Eileen Voynick to Board of Directors

Veradigm Strengthens Award-Winning Revenue Cycle Services Portfolio with Acquisition of Full-Service RCM Company

$MDRX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4) (Amendment)

Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4)

$MDRX Press Releases

Fastest customizable press release news feed in the world

Veradigm Advances Deeper Clinical Insights Through NLP-Enhanced EHR Data

Automated Medical Chart Retrieval Expands to 300,000+ U.S. Healthcare Providers via Veradigm eChart Courier

Veradigm Ranked Top Vendor by KLAS

$MDRX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Veradigm downgraded by Deutsche Bank with a new price target

Barclays initiated coverage on Veradigm with a new price target

Veradigm downgraded by Argus

$MDRX Market Insights

Live Market Insights

TD Cowen Maintains Buy on Veradigm, Lowers Price Target to $15

Deutsche Bank Downgrades Veradigm to Hold, Lowers Price Target to $10

Sprinklr To Replace Veradigm In S&P SmallCap 600 Effective Prior To Opening Of Trading On March 4, 2024

$MDRX SEC Filings

SEC Form 8-K filed by Veradigm Inc.

SEC Form NT 10-Q filed by Veradigm Inc.

SEC Form 8-K filed by Veradigm Inc.

$MDRX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

SEC Form SC 13G filed by Veradigm Inc.

SEC Form SC 13D filed by Veradigm Inc.

$MDRX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP General Counsel Vakharia Tejal covered exercise/tax liability with 1,223 shares, decreasing direct ownership by 0.38% to 320,877 units (SEC Form 4)

Director Altman Elizabeth Ann was granted 42,106 shares, increasing direct ownership by 118% to 77,658 units (SEC Form 4)

CEO Langan Thomas was granted 157,895 shares, increasing direct ownership by 91% to 331,902 units (SEC Form 4)

$MDRX Financials

Live finance-specific insights

Veradigm to Release Fourth Quarter and Fiscal Year 2022 Financial Results March 1

Veradigm Announces New Share Repurchase Program and Initial Financial Guidance for Fiscal 2023

Allscripts announces third quarter of 2022 results

Recent Analyst Ratings for
$MDRX

$MDRX
Leadership Updates

$MDRX
Insider Purchases

$MDRX
Press Releases

$MDRX
Analyst Ratings

$MDRX
Market Insights

$MDRX
SEC Filings

$MDRX
Large Ownership Changes

$MDRX
Insider Trading

$MDRX
Financials